| PHARVARIS N.V. EO -,12 |
| Niederlande |
| Gesundheit |
| NL00150005Y4 / A2QNWS |
| 9EN (Frankfurt) / PHVS (NASDAQ) |
| FRA:9EN, ETR:9EN, 9EN:GR, NASDAQ:PHVS |
| - |
| https://pharvaris.com/ |
|
Pharvaris N.V. is a biopharmaceutical company that specializes in discovering, developing, and commercializing innovative therapies to treat hereditary angioedema (HAE) and other bradykinin B2 receptor-mediated diseases. With its headquarters in Leid..
>Volltext.. |
| 1511.44 Mio. EUR |
| 1185.22 Mio. EUR |
| - |
| -159.23 Mio. EUR |
| -156.33 Mio. EUR |
| -2.78 EUR |
| 0.59 Mio. EUR |
| 334.53 Mio. EUR |
| -130.05 Mio. EUR |
| 12.56 |
| - |
| -19.59% |
| - |
| - |
| - |
| - |
| PHARVARIS |
| 01.04.26 |
|